The US Electromedical Devices market is demonstrating robust growth, driven by advancements in medical technology, rising adoption of connected health solutions, and an increasingly aging population. The market size was valued at USD 18,200 Million in 2025 and is expected to reach USD 32,900 Million by 2035, expanding at a CAGR of 5.5% from 2024 to 2035.
The economic impact of tariffs on "US Electromedical Devices".
US Electromedical Devices Market Growth Drivers
Increasing prevalence of chronic diseases such as diabetes, cardiovascular disorders, and neurological conditions is driving heightened demand for electromedical devices. Companies like Medtronic are expanding their portfolio of wearable monitoring devices and insulin pumps to address these needs, leading to better disease management and patient outcomes.
The integration of Artificial Intelligence (AI) and Internet of Things (IoT) into electromedical devices is enabling real-time monitoring, diagnostics, and data analytics. GE Healthcare, for instance, has launched AI-powered portable ultrasound systems, providing enhanced diagnostic accuracy and remote collaboration capabilities, which boost both clinical efficiency and patient care.
US Electromedical Devices Market Trends
Remote patient monitoring (RPM) and telemedicine-enabled electromedical devices are gaining high adoption. Philips, as an example, reported a significant increase in the deployment of their RPM devices, resulting in more proactive patient care and reduced hospital readmissions during 2023-2024.
Miniaturization and wearable technology are key trends shaping the US market. Abbott Laboratories has continued to innovate with devices like the FreeStyle Libre, a compact continuous glucose monitoring system that offers discrete, real-time monitoring, which encourages patient adherence and expands use beyond clinical settings.
US Electromedical Devices Market Opportunity
The expansion of home healthcare and outpatient care settings creates opportunities for companies to market user-friendly, portable, and cost-effective electromedical devices, as seen with ResMed’s suite of home respiratory care solutions.
The proliferation of 5G connectivity offers an opportunity to unlock more advanced remote diagnostics and therapeutic interventions, facilitating real-time, high-speed data transmission for devices from companies like Siemens Healthineers.
US Electromedical Devices Market Revenue (USD Million), 2020-2035
According to the chart, the US Electromedical Devices market revenue has shown consistent year-on-year growth from 2020 to 2035. In 2020, the market was valued at USD 13,200 Million and has steadily increased, reaching USD 18,200 Million in 2025. The strong upward trend continues, crossing USD 25,800 Million by 2030, and is projected to reach USD 32,900 Million by 2035. This growth is primarily driven by innovations in healthcare technology, rising chronic disease burdens, and growing investments in home-based medical devices. The robust CAGR of 5.5% reflects increased adoption across hospitals, ambulatory settings, and home healthcare, underlining the dynamic expansion trajectory of the US electromedical devices sector.
US Electromedical Devices Market by Regions Share (%), 2025
The 2025 regional share pie chart depicts that the South region holds the largest share of the US electromedical devices market at 32%, followed by the West at 27%. The Midwest accounts for 19%, while the Northeast represents 16%. Other smaller regions contribute 6%. The dominance of the South and West can be attributed to the concentration of leading healthcare institutions, higher healthcare expenditure, and greater adoption of innovative electromedical technologies. The Midwest and Northeast also maintain significant shares owing to the presence of established imaging and diagnostic centers, though they lag the market leaders slightly.
US Electromedical Devices Recent Developments
In March 2024, Medtronic announced the launch of its next-generation wearable cardiac monitoring device, the SeeQ™ II, after securing FDA clearance. This device offers continuous remote arrhythmia detection with extended battery life and improved patient comfort, further strengthening Medtronic’s leadership in remote cardiac care.
In May 2024, GE Healthcare introduced an AI-powered upgrade to its Vscan pocket ultrasound platform, delivering faster image acquisition and real-time disease screening at the point of care. This development is expected to accelerate the adoption of point-of-care ultrasound across US clinics and outpatient centers.
In April 2024, Abbott Laboratories expanded its FreeStyle Libre continuous glucose monitoring portfolio with the launch of Libre Sense, a wearable biosensor designed for wellness and sports performance, reflecting the growing convergence between medical and consumer health applications.
Press Releases